Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database.

CONTEXT People with severe mental illness (SMI) appear to have an elevated risk of death from cardiovascular disease, but results regarding cancer mortality are conflicting. OBJECTIVE To estimate this excess mortality and the contribution of antipsychotic medication, smoking, and social deprivation. DESIGN Retrospective cohort study. SETTING United Kingdom's General Practice Research Database. Patients Two cohorts were compared: people with SMI diagnoses and people without such diagnoses. Main Outcome Measure Mortality rates for coronary heart disease (CHD), stroke, and the 7 most common cancers in the United Kingdom. RESULTS A total of 46 136 people with SMI and 300 426 without SMI were selected for the study. Hazard ratios (HRs) for CHD mortality in people with SMI compared with controls were 3.22 (95% confidence interval [CI], 1.99-5.21) for people 18 through 49 years old, 1.86 (95% CI, 1.63-2.12) for those 50 through 75 years old, and 1.05 (95% CI, 0.92-1.19) for those older than 75 years. For stroke deaths, the HRs were 2.53 (95% CI, 0.99-6.47) for those younger than 50 years, 1.89 (95% CI, 1.50-2.38) for those 50 through 75 years old, and 1.34 (95% CI, 1.17-1.54) for those older than 75 years. The only significant result for cancer deaths was an unadjusted HR for respiratory tumors of 1.32 (95% CI, 1.04-1.68) for those 50 to 75 years old, which lost statistical significance after controlling for smoking and social deprivation. Increased HRs for CHD mortality occurred irrespective of sex, SMI diagnosis, or prescription of antipsychotic medication during follow-up. However, a higher prescribed dose of antipsychotics predicted greater risk of mortality from CHD and stroke. CONCLUSIONS This large community sample demonstrates that people with SMI have an increased risk of death from CHD and stroke that is not wholly explained by antipsychotic medication, smoking, or social deprivation scores. Rates of nonrespiratory cancer mortality were not raised. Further research is required concerning prevention of this mortality, including cardiovascular risk assessment, monitoring of antipsychotic medication, and attention to diet and exercise.

[1]  B. Schmand,et al.  Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users , 2006, Journal of psychopharmacology.

[2]  P. Sachdev,et al.  Brain reserve and dementia: a systematic review , 2005, Psychological Medicine.

[3]  A. Molero-Chamizo.  [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion]. , 2005, Revista de neurologia.

[4]  I. Levav,et al.  Cancer in schizophrenia: is the risk higher or lower? , 2005, Schizophrenia Research.

[5]  John M Davis,et al.  Physical health monitoring of patients with schizophrenia. , 2004, The American journal of psychiatry.

[6]  C. Johansen,et al.  Risk for cancer in parents of patients with schizophrenia. , 2004, The American journal of psychiatry.

[7]  Trevor R. Norman,et al.  Selective Effects of Acute Serotonin and Catecholamine Depletion on Memory in Healthy Women , 2004, Journal of psychopharmacology.

[8]  L. Degenhardt,et al.  The external validity of results derived from ecstasy users recruited using purposive sampling strategies. , 2004, Drug and alcohol dependence.

[9]  Robert F. Reynolds,et al.  Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia , 2004, The Journal of nervous and mental disease.

[10]  R. McCreadie,et al.  Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. , 2003, The British journal of psychiatry : the journal of mental science.

[11]  E. Zarahn,et al.  Exploring the Neural Basis of Cognitive Reserve , 2003, Journal of clinical and experimental neuropsychology.

[12]  Corri Black,et al.  Validity of the General Practice Research Database , 2003, Pharmacotherapy.

[13]  C. Holman,et al.  Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. , 2003, The British journal of psychiatry : the journal of mental science.

[14]  S. Bazire.  Psychotropic Drug Directory: The Professionals' Pocket Handbook and Aide Memoire , 2003 .

[15]  B. Sahakian,et al.  Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users , 2002, Psychopharmacology.

[16]  V. Lehtinen,et al.  Mental disorders and cause-specific mortality , 2001, British Journal of Psychiatry.

[17]  E. Arnesen,et al.  Cause-specific mortality in psychiatric patients after deinstitutionalisation , 2001, British Journal of Psychiatry.

[18]  P. Sparén,et al.  Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study , 2000, BMJ : British Medical Journal.

[19]  Z. Szabo,et al.  Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). , 2000, Toxicology letters.

[20]  R. McCreadie,et al.  Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. , 1999, The American journal of psychiatry.

[21]  M. Buhot,et al.  Serotonin receptors and cognitive behaviour--an update. , 1999, IDrugs : the investigational drugs journal.

[22]  B. Barraclough,et al.  Excess mortality of mental disorder , 1998, British Journal of Psychiatry.

[23]  Steve Brown.  Excess mortality of schizophrenia , 1997, British Journal of Psychiatry.

[24]  J. Lindeboom,et al.  The effects of intelligence and education on the development of dementia. A test of the brain reserve hypothesis , 1997, Psychological Medicine.

[25]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[26]  T. Kendrick,et al.  Cardiovascular and Respiratory Risk Factors and Symptoms among General Practice Patients with Long-Term Mental Illness , 1996, British Journal of Psychiatry.

[27]  A. Meneses,et al.  Modification of 8-OH-DPAT effects on learning by manipulation of the assay conditions. , 1994, Behavioral and neural biology.

[28]  A Haines,et al.  Accuracy of diagnosis of psychosis on general practice computer system. , 1993, BMJ.

[29]  H. Morgenstern,et al.  Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the multicenter AIDS Cohort Study (MACS). , 1993, Journal of acquired immune deficiency syndromes.

[30]  V. Carstairs,et al.  Which deprivation? A comparison of selected deprivation indexes. , 1991, Journal of public health medicine.

[31]  A. Hunter.  Serotonergic involvement in learning and memory. , 1989, Biochemical Society transactions.

[32]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.